Davis Beth E, Reid John K, Cockcroft Donald W
Division of Respiratory Medicine, Department of Medicine, Royal University Hospital, Saskatoon, Saskatchewan.
Can Respir J. 2003 Jan-Feb;10(1):23-6. doi: 10.1155/2003/148740.
Loss of bronchoprotection routinely follows regular treatment with beta2-agonists. There are no data on the effects on bronchoprotection for thrice weekly use of a beta2-agonist.
A double-blind, randomized, placebo controlled crossover trial was conducted to investigate the effects of thrice weekly administration of 12 microg of formoterol versus placebo on bronchoprotection against methacholine. As an expected positive control, formoterol 12 microg once daily was also evaluated.
There was no significant difference versus placebo in the bronchoprotective effects of 12 microg of formoterol administered on day 8, following daily treatment for seven days or treatment every other day (analysis of variance P=0.34). However, a nonsignificant trend towards lower concentration of methacholine that caused a 20% fall in forced expiratory volume in 1 s developed only following the daily formoterol dosing.
Thrice weekly dosing does not result in the development of tolerance to bronchoprotection against the direct acting stimulus methacholine.
常规使用β2受体激动剂进行治疗后，支气管保护作用通常会丧失。目前尚无关于每周三次使用β2受体激动剂对支气管保护作用影响的数据。
进行了一项双盲、随机、安慰剂对照的交叉试验，以研究每周三次给予12微克福莫特罗与安慰剂相比，对乙酰甲胆碱支气管保护作用的影响。作为预期的阳性对照，还评估了每日一次给予12微克福莫特罗的情况。
在连续7天每日治疗或隔日治疗后，第8天给予12微克福莫特罗的支气管保护作用与安慰剂相比无显著差异（方差分析P = 0.34）。然而，仅在每日给予福莫特罗后，导致1秒用力呼气量下降20%的乙酰甲胆碱浓度有降低的趋势，但不显著。
每周三次给药不会导致对直接作用刺激物乙酰甲胆碱的支气管保护作用产生耐受性。
